| scholarly article | Q13442814 |
| P50 | author | Eliezer Masliah | Q28324209 |
| Edward Rockenstein | Q28324218 | ||
| Robert A. Marr | Q127690892 | ||
| P2093 | author name string | Brian Spencer | |
| Inder M Verma | |||
| Anthony Adame | |||
| Rewati Potkar | |||
| Ryan Gindi | |||
| Sarah Michael | |||
| P2860 | cites work | Progressive accumulation of amyloid-beta oligomers in Alzheimer's disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins | Q24329069 |
| Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory | Q24645499 | ||
| Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake | Q24656613 | ||
| Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo | Q28131779 | ||
| Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition | Q28143799 | ||
| APOE genotype effects on Alzheimer's disease onset and epidemiology | Q28265282 | ||
| A mouse model of amyloid beta oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. | Q51059487 | ||
| CD10 (CALLA)/neutral endopeptidase 24.11 modulates inflammatory peptide-induced changes in neutrophil morphology, migration, and adhesion proteins and is itself regulated by neutrophil activation | Q67700741 | ||
| Neutral endopeptidase can hydrolyze beta-amyloid(1-40) but shows no effect on beta-amyloid precursor protein metabolism | Q71530371 | ||
| Up-regulation of neutral endopeptidase (CALLA) in human neutrophils by granulocyte-macrophage colony-stimulating factor | Q72790210 | ||
| Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders | Q29614754 | ||
| Intracellular amyloid-beta in Alzheimer's disease | Q29615626 | ||
| High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation | Q29616564 | ||
| Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Abeta oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice | Q30491245 | ||
| Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease. | Q30833707 | ||
| Synaptic targeting by Alzheimer's-related amyloid beta oligomers. | Q33288786 | ||
| Long-term neprilysin gene transfer is associated with reduced levels of intracellular Abeta and behavioral improvement in APP transgenic mice | Q33384861 | ||
| Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases | Q33613123 | ||
| Expression of neprilysin in skeletal muscle reduces amyloid burden in a transgenic mouse model of Alzheimer disease | Q33713881 | ||
| Drug and gene delivery to the brain: the vascular route | Q35003855 | ||
| Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer's disease | Q35246412 | ||
| Targeted delivery of proteins across the blood-brain barrier | Q35762072 | ||
| Intracellular and extracellular Abeta, a tale of two neuropathologies | Q36075469 | ||
| A 10-amino acid sequence of fibroblast growth factor 2 is sufficient for its mitogenic activity on neural progenitor cells. | Q36247964 | ||
| Increasing Cu bioavailability inhibits Abeta oligomers and tau phosphorylation | Q37061979 | ||
| Impact of intracellular beta-amyloid in transgenic animals and cell models | Q37103004 | ||
| Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases | Q37461136 | ||
| NEP-like endopeptidases and Alzheimer's disease [corrected]. | Q37678534 | ||
| Aggregation and catabolism of disease-associated intra-Abeta mutations: reduced proteolysis of AbetaA21G by neprilysin | Q38257065 | ||
| Overexpression of neprilysin reduces alzheimer amyloid-beta42 (Abeta42)-induced neuron loss and intraneuronal Abeta42 deposits but causes a reduction in cAMP-responsive element-binding protein-mediated transcription, age-dependent axon pathology, an | Q39627415 | ||
| Ginsenoside Rg3 promotes beta-amyloid peptide degradation by enhancing gene expression of neprilysin | Q39882978 | ||
| Gleevec increases levels of the amyloid precursor protein intracellular domain and of the amyloid-beta degrading enzyme neprilysin | Q40108106 | ||
| High intracellular concentrations of amyloid-beta block nuclear translocation of phosphorylated CREB. | Q40116273 | ||
| Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model | Q40379114 | ||
| Lysosomal pathology associated with alpha-synuclein accumulation in transgenic models using an eGFP fusion protein. | Q40447154 | ||
| Presynaptic localization of neprilysin contributes to efficient clearance of amyloid-beta peptide in mouse brain. | Q40594671 | ||
| Human neprilysin is capable of degrading amyloid beta peptide not only in the monomeric form but also the pathological oligomeric form | Q40634900 | ||
| Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. | Q40661439 | ||
| Hippocampal and neocortical involvement in normal brain aging and dementia: morphological and neurochemical profile of the vulnerable circuits | Q41011970 | ||
| Elimination of the class A scavenger receptor does not affect amyloid plaque formation or neurodegeneration in transgenic mice expressing human amyloid protein precursors | Q41700588 | ||
| Cytokine-mediated inhibition of fibrillar amyloid-beta peptide degradation by human mononuclear phagocytes | Q42020497 | ||
| Neuropeptide Y fragments derived from neprilysin processing are neuroprotective in a transgenic model of Alzheimer's disease | Q42593650 | ||
| Early formation of mature amyloid-beta protein deposits in a mutant APP transgenic model depends on levels of Abeta(1-42). | Q43825281 | ||
| Antisense directed at the Abeta region of APP decreases brain oxidative markers in aged senescence accelerated mice | Q44985177 | ||
| High beta-secretase activity elicits neurodegeneration in transgenic mice despite reductions in amyloid-beta levels: implications for the treatment of Alzheimer disease | Q45286392 | ||
| Herpes simplex virus RNAi and neprilysin gene transfer vectors reduce accumulation of Alzheimer's disease-related amyloid-beta peptide in vivo | Q45418795 | ||
| Transduction of liver cells by lentiviral vectors: analysis in living animals by fluorescence imaging. | Q45991699 | ||
| GEPT extract reduces Abeta deposition by regulating the balance between production and degradation of Abeta in APPV717I transgenic mice | Q46056814 | ||
| Production and purification of lentiviral vectors | Q46172190 | ||
| Anti-amyloid activity of neprilysin in plaque-bearing mouse models of Alzheimer's disease | Q47884196 | ||
| Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death | Q48110123 | ||
| Neprilysin-sensitive synapse-associated amyloid-beta peptide oligomers impair neuronal plasticity and cognitive function. | Q48569616 | ||
| Metabolic regulation of brain Abeta by neprilysin | Q48869458 | ||
| Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation | Q48960635 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Alzheimer's disease | Q11081 |
| P304 | page(s) | e16575 | |
| P577 | publication date | 2011-01-01 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Peripheral delivery of a CNS targeted, metalo-protease reduces aβ toxicity in a mouse model of Alzheimer's disease | |
| P478 | volume | 6 |
| Q36086721 | A brain-targeted, modified neurosin (kallikrein-6) reduces α-synuclein accumulation in a mouse model of multiple system atrophy |
| Q36870087 | A highly secreted sulphamidase engineered to cross the blood-brain barrier corrects brain lesions of mice with mucopolysaccharidoses type IIIA. |
| Q33793059 | A neuroprotective brain-penetrating endopeptidase fusion protein ameliorates Alzheimer disease pathology and restores neurogenesis |
| Q38256360 | Amyloid-clearing proteins and their epigenetic regulation as a therapeutic target in Alzheimer's disease |
| Q40706306 | Applications of ApoB LDLR-Binding Domain Approach for the Development of CNS-Penetrating Peptides for Alzheimer's Disease |
| Q37961852 | Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer's disease? |
| Q38259551 | Aβ degradation or cerebral perfusion? Divergent effects of multifunctional enzymes |
| Q38878922 | Aβ-Degrading Proteases: Therapeutic Potential in Alzheimer Disease |
| Q49950868 | Cognitive performance of patients with chronic heart failure on sacubitril/valsartan : A retrospective cohort study |
| Q42235059 | Comparison of five peptide vectors for improved brain delivery of the lysosomal enzyme arylsulfatase A. |
| Q34071221 | Distinctive RNA expression profiles in blood associated with Alzheimer disease after accounting for white matter hyperintensities |
| Q30650119 | ESCRT-mediated uptake and degradation of brain-targeted α-synuclein single chain antibody attenuates neuronal degeneration in vivo |
| Q35596571 | Engineered antibody therapies coming of age for aging brains |
| Q27684924 | Engineering Neprilysin Activity and Specificity to Create a Novel Therapeutic for Alzheimer’s Disease |
| Q33695622 | HIV-1 Transactivator Protein Induces ZO-1 and Neprilysin Dysfunction in Brain Endothelial Cells via the Ras Signaling Pathway. |
| Q34430288 | Human P301L-mutant tau expression in mouse entorhinal-hippocampal network causes tau aggregation and presynaptic pathology but no cognitive deficits |
| Q51746979 | Identification and characterization of highly versatile peptide-vectors that bind non-competitively to the low-density lipoprotein receptor for in vivo targeting and delivery of small molecules and protein cargos. |
| Q38601445 | Impact of Insulin Degrading Enzyme and Neprilysin in Alzheimer's Disease Biology: Characterization of Putative Cognates for Therapeutic Applications |
| Q38246688 | Improved brain uptake of peptide-based CNS drugs via alternative routes of administrations of its nanocarrier delivery systems: a promising strategy for CNS targeting delivery of peptides. |
| Q41264931 | Is Entresto good for the brain? |
| Q36512589 | Lentivirus mediated delivery of neurosin promotes clearance of wild-type α-synuclein and reduces the pathology in an α-synuclein model of LBD. |
| Q39038686 | Long-term neprilysin inhibition - implications for ARNIs |
| Q48352528 | Neprilysin, cardiovascular, and Alzheimer's diseases: the therapeutic split? |
| Q27316651 | Neuregulin 1 improves cognitive deficits and neuropathology in an Alzheimer's disease model |
| Q36204147 | Ratio of apoB/LDL: a potential clinical index for vascular cognitive impairment |
| Q89208306 | Selective targeting of 3 repeat Tau with brain penetrating single chain antibodies for the treatment of neurodegenerative disorders |
| Q37561302 | Serum ApoB levels in depressive patients: associated with cognitive deficits |
| Q48547451 | Stimulating the Activity of Amyloid-Beta Degrading Enzymes: A Novel Approach for the Therapeutic Manipulation of Amyloid-Beta Levels. |
| Q37556990 | Sustained peripheral depletion of amyloid-β with a novel form of neprilysin does not affect central levels of amyloid-β. |
| Q36489317 | Systemic Central Nervous System (CNS)-targeted Delivery of Neuropeptide Y (NPY) Reduces Neurodegeneration and Increases Neural Precursor Cell Proliferation in a Mouse Model of Alzheimer Disease |
| Q64777173 | Systemic peptide mediated delivery of an siRNA targeting α-syn in the CNS ameliorates the neurodegenerative process in a transgenic model of Lewy body disease |
| Q90550738 | Targeting Ligands Deliver Model Drug Cargo into the Central Nervous System along Autonomic Neurons |
| Q37312010 | Targeting receptor-mediated transport for delivery of biologics across the blood-brain barrier |
| Q21296650 | The Alzheimer's amyloid-degrading peptidase, neprilysin: can we control it? |
| Q61449202 | Transcytosis to Cross the Blood Brain Barrier, New Advancements and Challenges |
| Q37960498 | Utilization of APPswe/PS1dE9 Transgenic Mice in Research of Alzheimer's Disease: Focus on Gene Therapy and Cell-Based Therapy Applications |
Search more.